JP2014501232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501232A5 JP2014501232A5 JP2013543700A JP2013543700A JP2014501232A5 JP 2014501232 A5 JP2014501232 A5 JP 2014501232A5 JP 2013543700 A JP2013543700 A JP 2013543700A JP 2013543700 A JP2013543700 A JP 2013543700A JP 2014501232 A5 JP2014501232 A5 JP 2014501232A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- isopropyl
- dihydroxy
- triazole
- ylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims description 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims description 2
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000005936 piperidyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- -1 4-morpholin-4-ylmethyl-phenyl Chemical group 0.000 claims 19
- 238000000034 method Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000003880 polar aprotic solvent Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229910052707 ruthenium Inorganic materials 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- NCROGRSEZXPSAB-FQEVSTJZSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-5-[4-[[(3s)-3-(dimethylamino)pyrrolidin-1-yl]methyl]phenyl]-n-ethyltriazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1C(C=C1)=CC=C1CN1CC[C@H](N(C)C)C1 NCROGRSEZXPSAB-FQEVSTJZSA-N 0.000 claims 1
- HACUQVIGSVHRDG-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyl-5-(4-morpholin-4-ylanilino)triazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1NC(C=C1)=CC=C1N1CCOCC1 HACUQVIGSVHRDG-UHFFFAOYSA-N 0.000 claims 1
- FUMWVJMVSTVBNU-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyl-5-[(4-morpholin-4-ylphenyl)methylamino]triazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1NCC(C=C1)=CC=C1N1CCOCC1 FUMWVJMVSTVBNU-UHFFFAOYSA-N 0.000 claims 1
- CZOUDHZUZWUMJW-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyl-5-[(4-piperidin-1-ylbenzoyl)amino]triazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1NC(=O)C(C=C1)=CC=C1N1CCCCC1 CZOUDHZUZWUMJW-UHFFFAOYSA-N 0.000 claims 1
- ULOKKHFOJOFZTK-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyl-5-[(4-pyrrolidin-1-ylbenzoyl)amino]triazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1NC(=O)C(C=C1)=CC=C1N1CCCC1 ULOKKHFOJOFZTK-UHFFFAOYSA-N 0.000 claims 1
- AVBUQYSOQNEWSM-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyl-5-[4-(1,2-oxazolidin-2-ylmethyl)phenyl]triazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1C(C=C1)=CC=C1CN1CCCO1 AVBUQYSOQNEWSM-UHFFFAOYSA-N 0.000 claims 1
- ZSOQWPOVGAAMDL-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyl-5-[4-(imidazol-1-ylmethyl)phenyl]triazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1C(C=C1)=CC=C1CN1C=CN=C1 ZSOQWPOVGAAMDL-UHFFFAOYSA-N 0.000 claims 1
- CKHCXYIYTCETLS-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyl-5-[4-(morpholin-4-ylmethyl)phenyl]triazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1C(C=C1)=CC=C1CN1CCOCC1 CKHCXYIYTCETLS-UHFFFAOYSA-N 0.000 claims 1
- VMXCKZIFERGZDF-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyl-5-[4-(piperidin-1-ylmethyl)phenyl]triazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1C(C=C1)=CC=C1CN1CCCCC1 VMXCKZIFERGZDF-UHFFFAOYSA-N 0.000 claims 1
- SJDWGCMBVASEIX-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyl-5-[4-(pyrrolidin-1-ylmethyl)phenyl]triazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1C(C=C1)=CC=C1CN1CCCC1 SJDWGCMBVASEIX-UHFFFAOYSA-N 0.000 claims 1
- PMFMGZJFZPEYMR-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyl-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]triazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1C(C=C1)=CC=C1CN1CCN(C)CC1 PMFMGZJFZPEYMR-UHFFFAOYSA-N 0.000 claims 1
- KEKZMGAKYRLNTP-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyl-5-[4-[(4-phenylpiperazin-1-yl)methyl]phenyl]triazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1C(C=C1)=CC=C1CN(CC1)CCN1C1=CC=CC=C1 KEKZMGAKYRLNTP-UHFFFAOYSA-N 0.000 claims 1
- QIWVPINCEFIBLF-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyl-5-[4-[[ethyl(2-hydroxyethyl)amino]methyl]phenyl]triazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1C1=CC=C(CN(CC)CCO)C=C1 QIWVPINCEFIBLF-UHFFFAOYSA-N 0.000 claims 1
- MFYWKUOGYVQFJM-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyl-5-[[4-(3-hydroxypiperidin-1-yl)benzoyl]amino]triazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1NC(=O)C(C=C1)=CC=C1N1CCCC(O)C1 MFYWKUOGYVQFJM-UHFFFAOYSA-N 0.000 claims 1
- NCOGBAPNIBYJGP-UHFFFAOYSA-N 1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyl-5-[[4-(morpholin-4-ylmethyl)cyclohexanecarbonyl]amino]triazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1NC(=O)C(CC1)CCC1CN1CCOCC1 NCOGBAPNIBYJGP-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- CAIJFEGIAAQWDA-UHFFFAOYSA-N 4-[5-(4-morpholin-4-ylanilino)triazol-1-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=CN=N2)NC=2C=CC(=CC=2)N2CCOCC2)=C1O CAIJFEGIAAQWDA-UHFFFAOYSA-N 0.000 claims 1
- XOSSGUMZKOBKKC-UHFFFAOYSA-N 4-[5-[(4-morpholin-4-ylphenyl)methylamino]triazol-1-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=CN=N2)NCC=2C=CC(=CC=2)N2CCOCC2)=C1O XOSSGUMZKOBKKC-UHFFFAOYSA-N 0.000 claims 1
- YAKSCLIHWCEFNU-UHFFFAOYSA-N 4-[5-[4-(1,2-oxazolidin-2-ylmethyl)phenyl]triazol-1-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound CC(C)c1cc(c(O)cc1O)-n1nncc1-c1ccc(CN2CCCO2)cc1 YAKSCLIHWCEFNU-UHFFFAOYSA-N 0.000 claims 1
- QETISTDEYMGRCN-UHFFFAOYSA-N 4-[5-[4-(morpholin-4-ylmethyl)phenyl]triazol-1-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=CN=N2)C=2C=CC(CN3CCOCC3)=CC=2)=C1O QETISTDEYMGRCN-UHFFFAOYSA-N 0.000 claims 1
- ZJSCBXBMQFTBAY-UHFFFAOYSA-N 4-[5-[4-[(3-hydroxypiperidin-1-yl)methyl]phenyl]triazol-1-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=CN=N2)C=2C=CC(CN3CC(O)CCC3)=CC=2)=C1O ZJSCBXBMQFTBAY-UHFFFAOYSA-N 0.000 claims 1
- GBUFUJGPAXHPDH-UHFFFAOYSA-N 4-[5-[4-[(4-benzylpiperazin-1-yl)methyl]phenyl]triazol-1-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=CN=N2)C=2C=CC(CN3CCN(CC=4C=CC=CC=4)CC3)=CC=2)=C1O GBUFUJGPAXHPDH-UHFFFAOYSA-N 0.000 claims 1
- MKBBWHFACZDCOH-UHFFFAOYSA-N 4-[5-[4-[(4-phenylpiperazin-1-yl)methyl]phenyl]triazol-1-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=CN=N2)C=2C=CC(CN3CCN(CC3)C=3C=CC=CC=3)=CC=2)=C1O MKBBWHFACZDCOH-UHFFFAOYSA-N 0.000 claims 1
- DEYGCWDOMSNVOT-UHFFFAOYSA-N 4-[5-[4-[[2-(2-hydroxyethyl)piperidin-1-yl]methyl]phenyl]triazol-1-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=CN=N2)C=2C=CC(CN3C(CCCC3)CCO)=CC=2)=C1O DEYGCWDOMSNVOT-UHFFFAOYSA-N 0.000 claims 1
- JOXXZWQGNIULBA-UHFFFAOYSA-N 4-[5-[4-[[ethyl(2-hydroxyethyl)amino]methyl]phenyl]triazol-1-yl]-6-propan-2-ylbenzene-1,3-diol Chemical compound C1=CC(CN(CCO)CC)=CC=C1C1=CN=NN1C1=CC(C(C)C)=C(O)C=C1O JOXXZWQGNIULBA-UHFFFAOYSA-N 0.000 claims 1
- DXTFENZEURBOIF-UHFFFAOYSA-N 4-propan-2-yl-6-[5-[4-(pyrrolidin-1-ylmethyl)phenyl]triazol-1-yl]benzene-1,3-diol Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=CN=N2)C=2C=CC(CN3CCCC3)=CC=2)=C1O DXTFENZEURBOIF-UHFFFAOYSA-N 0.000 claims 1
- AIMKFQOZDDCIAX-UHFFFAOYSA-N 5-[4-(diethylaminomethyl)phenyl]-1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyltriazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1C1=CC=C(CN(CC)CC)C=C1 AIMKFQOZDDCIAX-UHFFFAOYSA-N 0.000 claims 1
- KGAKOACEBMLXIK-UHFFFAOYSA-N 5-[4-[(4-benzylpiperazin-1-yl)methyl]phenyl]-1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyltriazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1C(C=C1)=CC=C1CN(CC1)CCN1CC1=CC=CC=C1 KGAKOACEBMLXIK-UHFFFAOYSA-N 0.000 claims 1
- GRWUWTJRPDVUNR-UHFFFAOYSA-N 5-[4-[[2-(diethylamino)ethylamino]methyl]phenyl]-1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyltriazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1C1=CC=C(CNCCN(CC)CC)C=C1 GRWUWTJRPDVUNR-UHFFFAOYSA-N 0.000 claims 1
- OJKALDMOCOACDI-UHFFFAOYSA-N 5-[4-[[3-(diethylamino)propylamino]methyl]phenyl]-1-(2,4-dihydroxy-5-propan-2-ylphenyl)-n-ethyltriazole-4-carboxamide Chemical compound CCNC(=O)C=1N=NN(C=2C(=CC(O)=C(C(C)C)C=2)O)C=1C1=CC=C(CNCCCN(CC)CC)C=C1 OJKALDMOCOACDI-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000009182 Parasitemia Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- CJFMDQHCWOVQSO-UHFFFAOYSA-N n-(2-chloroethyl)-1-(2,4-dihydroxy-5-propan-2-ylphenyl)-5-[4-(morpholin-4-ylmethyl)phenyl]triazole-4-carboxamide Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=C(C(=O)NCCCl)N=N2)C=2C=CC(CN3CCOCC3)=CC=2)=C1O CJFMDQHCWOVQSO-UHFFFAOYSA-N 0.000 claims 1
- ACJSGTGRAKYUQY-UHFFFAOYSA-N n-[3-(2,4-dihydroxy-5-propan-2-ylphenyl)triazol-4-yl]-4-(3-hydroxypiperidin-1-yl)benzamide Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=CN=N2)NC(=O)C=2C=CC(=CC=2)N2CC(O)CCC2)=C1O ACJSGTGRAKYUQY-UHFFFAOYSA-N 0.000 claims 1
- YGLOTNFZFCMVRU-UHFFFAOYSA-N n-[3-(2,4-dihydroxy-5-propan-2-ylphenyl)triazol-4-yl]-4-(morpholin-4-ylmethyl)benzamide Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=CN=N2)NC(=O)C=2C=CC(CN3CCOCC3)=CC=2)=C1O YGLOTNFZFCMVRU-UHFFFAOYSA-N 0.000 claims 1
- JOMWZJLCZBJOBA-UHFFFAOYSA-N n-[3-(2,4-dihydroxy-5-propan-2-ylphenyl)triazol-4-yl]-4-(morpholin-4-ylmethyl)cyclohexane-1-carboxamide Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=CN=N2)NC(=O)C2CCC(CN3CCOCC3)CC2)=C1O JOMWZJLCZBJOBA-UHFFFAOYSA-N 0.000 claims 1
- CPGIJQOIMPLUKZ-UHFFFAOYSA-N n-[3-(2,4-dihydroxy-5-propan-2-ylphenyl)triazol-4-yl]-4-morpholin-4-ylbenzamide Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=CN=N2)NC(=O)C=2C=CC(=CC=2)N2CCOCC2)=C1O CPGIJQOIMPLUKZ-UHFFFAOYSA-N 0.000 claims 1
- FQJVHYHXQNUAOG-UHFFFAOYSA-N n-[3-(2,4-dihydroxy-5-propan-2-ylphenyl)triazol-4-yl]-4-pyrrolidin-1-ylbenzamide Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=CN=N2)NC(=O)C=2C=CC(=CC=2)N2CCCC2)=C1O FQJVHYHXQNUAOG-UHFFFAOYSA-N 0.000 claims 1
- DKKADLLUEKFSFF-UHFFFAOYSA-N n-cyclohexyl-1-(2,4-dihydroxy-5-propan-2-ylphenyl)-5-[4-(morpholin-4-ylmethyl)phenyl]triazole-4-carboxamide Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=C(C(=O)NC3CCCCC3)N=N2)C=2C=CC(CN3CCOCC3)=CC=2)=C1O DKKADLLUEKFSFF-UHFFFAOYSA-N 0.000 claims 1
- NCZKFFVXUCMMPH-UHFFFAOYSA-N n-cyclopentyl-1-(2,4-dihydroxy-5-propan-2-ylphenyl)-5-[4-(morpholin-4-ylmethyl)phenyl]triazole-4-carboxamide Chemical compound C1=C(O)C(C(C)C)=CC(N2C(=C(C(=O)NC3CCCC3)N=N2)C=2C=CC(CN3CCOCC3)=CC=2)=C1O NCZKFFVXUCMMPH-UHFFFAOYSA-N 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000004303 peritoneum Anatomy 0.000 claims 1
- 210000004224 pleura Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10195949 | 2010-12-20 | ||
| EP10195949.2 | 2010-12-20 | ||
| PCT/EP2011/072558 WO2012084602A1 (en) | 2010-12-20 | 2011-12-13 | Aryl triazole compounds with antitumoural activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014501232A JP2014501232A (ja) | 2014-01-20 |
| JP2014501232A5 true JP2014501232A5 (enExample) | 2016-01-07 |
Family
ID=43901588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543700A Pending JP2014501232A (ja) | 2010-12-20 | 2011-12-13 | 抗腫瘍活性を有するアリールトリアゾール化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9302998B2 (enExample) |
| EP (1) | EP2655345B1 (enExample) |
| JP (1) | JP2014501232A (enExample) |
| AR (1) | AR084361A1 (enExample) |
| CY (1) | CY1116297T1 (enExample) |
| DK (1) | DK2655345T3 (enExample) |
| ES (1) | ES2536980T3 (enExample) |
| HR (1) | HRP20150450T1 (enExample) |
| HU (1) | HUE025697T2 (enExample) |
| ME (1) | ME02144B (enExample) |
| PL (1) | PL2655345T3 (enExample) |
| PT (1) | PT2655345E (enExample) |
| RS (1) | RS53966B1 (enExample) |
| SI (1) | SI2655345T1 (enExample) |
| SM (1) | SMT201500115B (enExample) |
| WO (1) | WO2012084602A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1206714A1 (en) * | 2012-09-17 | 2016-01-15 | 霍夫曼-拉罗奇有限公司 | Triazole carboxamide derivatives |
| CN103275023B (zh) * | 2013-06-08 | 2015-10-07 | 浙江工业大学 | 1-芳基-1,2,3-三氮唑类化合物及其制备和应用 |
| CN107540624B (zh) * | 2016-06-29 | 2020-06-16 | 广州市恒诺康医药科技有限公司 | 热休克蛋白抑制剂及其制备方法和应用 |
| US10975030B2 (en) | 2016-10-31 | 2021-04-13 | University Of Kansas | Grp94 selective inhibitors and uses thereof |
| WO2019040869A1 (en) * | 2017-08-25 | 2019-02-28 | The Trustees Of Columbia University In The City Of New York | INHIBITORS OF IMPORTS OF PURINE IN PARASITES AND USES OF THESE INHIBITORS |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN110590686B (zh) * | 2019-10-31 | 2022-10-25 | 重庆大学 | 一种氮杂糖基1,2,3-三氮唑核苷化合物及其制备方法和应用 |
| WO2021137665A1 (ko) * | 2019-12-30 | 2021-07-08 | 이화여자대학교 산학협력단 | Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10315570A1 (de) | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Triazolderivate |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| GB0323810D0 (en) | 2003-10-10 | 2003-11-12 | Cancer Rec Tech Ltd | Pyridothiophene compounds |
| RS52642B (sr) | 2004-11-18 | 2013-06-28 | Synta Pharmaceuticals Corp. | Jedinjenja triazola koja modulišu aktivnost hsp90 |
| WO2006109846A1 (ja) | 2005-04-06 | 2006-10-19 | Takeda Pharmaceutical Company Limited | トリアゾール誘導体およびその用途 |
| JP2006306755A (ja) * | 2005-04-27 | 2006-11-09 | Nippon Kayaku Co Ltd | 新規なピラゾール誘導体とそれを有効成分とするｈｓｐ９０阻害剤 |
| US7781462B2 (en) * | 2005-07-25 | 2010-08-24 | Synta Pharmaceuticals Corp. | Compounds for the treatment of proliferative disorders |
| CA2664852A1 (en) * | 2006-10-03 | 2008-04-10 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of resorcinol derivatives |
| PL2118077T3 (pl) * | 2007-02-08 | 2015-05-29 | Synta Pharmaceuticals Corp | Związki triazolowe modulujące aktywność hsp90 |
| US20110065725A1 (en) | 2008-03-18 | 2011-03-17 | Glaxo Group Limited | Triazole amide derivatives for use in therapy |
| LT5623B (lt) | 2008-04-30 | 2010-01-25 | Biotechnologijos Institutas, , | 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti |
| US9156836B2 (en) | 2008-05-16 | 2015-10-13 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate HSP90 activity |
| US8106083B2 (en) | 2008-08-08 | 2012-01-31 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| WO2010017479A1 (en) | 2008-08-08 | 2010-02-11 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
-
2011
- 2011-12-13 DK DK11805449.3T patent/DK2655345T3/en active
- 2011-12-13 HR HRP20150450TT patent/HRP20150450T1/hr unknown
- 2011-12-13 JP JP2013543700A patent/JP2014501232A/ja active Pending
- 2011-12-13 WO PCT/EP2011/072558 patent/WO2012084602A1/en not_active Ceased
- 2011-12-13 RS RS20150294A patent/RS53966B1/sr unknown
- 2011-12-13 HU HUE11805449A patent/HUE025697T2/en unknown
- 2011-12-13 PL PL11805449T patent/PL2655345T3/pl unknown
- 2011-12-13 ME MEP-2015-62A patent/ME02144B/me unknown
- 2011-12-13 ES ES11805449.3T patent/ES2536980T3/es active Active
- 2011-12-13 SI SI201130488T patent/SI2655345T1/sl unknown
- 2011-12-13 PT PT118054493T patent/PT2655345E/pt unknown
- 2011-12-13 EP EP11805449.3A patent/EP2655345B1/en active Active
- 2011-12-13 US US13/996,359 patent/US9302998B2/en not_active Expired - Fee Related
- 2011-12-19 AR ARP110104771A patent/AR084361A1/es not_active Application Discontinuation
-
2015
- 2015-05-15 SM SM201500115T patent/SMT201500115B/xx unknown
- 2015-05-15 CY CY20151100441T patent/CY1116297T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014501232A5 (enExample) | ||
| ME02144B (me) | Jedinjenja aril triazola sa antitumorskom aktivnošću | |
| RU2361860C2 (ru) | Новые замещенные 3-сера-индолы | |
| ES2536191T3 (es) | Derivados de sulfonamida | |
| JP2020033357A5 (enExample) | ||
| JP2009507080A5 (enExample) | ||
| JP2014511869A5 (enExample) | ||
| RU2501791C2 (ru) | Производное триазола или его соль | |
| JP2018503661A5 (enExample) | ||
| JP2018502912A5 (enExample) | ||
| JP2015529192A5 (enExample) | ||
| JP2007039461A5 (enExample) | ||
| RU2005109561A (ru) | Новые производные аминоиндазолов в качестве лекарственных средств и содержащие их фармацевтические композиции | |
| JP2013519680A5 (enExample) | ||
| JP2013510859A5 (enExample) | ||
| JP2017524026A5 (enExample) | ||
| CA2918284A1 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| JP2008517976A5 (enExample) | ||
| JP2017524019A5 (enExample) | ||
| JP2016530322A5 (enExample) | ||
| RU2348628C2 (ru) | Замещенные циклопропильной группой оксазолидиноновые антибиотики и их производные | |
| JP2017524019A (ja) | Ｎｒ２ｂ受容体阻害剤としてのトリアゾール | |
| HRP20220327T1 (hr) | Supstituirani triazoli i postupci koji se na njih odnose | |
| JP2020516659A5 (enExample) | ||
| EP3148972A1 (en) | Pyrazolone derivatives as nitroxyl donors |